Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | Crizotinib | CCLE | pan-cancer | AAC | -0.016 | 0.7 |
mRNA | SJ-172550 | CTRPv2 | pan-cancer | AAC | -0.013 | 0.7 |
mRNA | JNK Inhibitor VIII | GDSC1000 | pan-cancer | AAC | -0.012 | 0.7 |
mRNA | tosedostat | CTRPv2 | pan-cancer | AAC | 0.012 | 0.7 |
mRNA | ISOX:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.012 | 0.7 |
mRNA | Nilotinib | FIMM | pan-cancer | AAC | 0.068 | 0.7 |
mRNA | cyanoquinoline 11 | CTRPv2 | pan-cancer | AAC | 0.017 | 0.7 |
mRNA | MLN2238 | CTRPv2 | pan-cancer | AAC | 0.011 | 0.7 |
mRNA | BRD-K34485477 | CTRPv2 | pan-cancer | AAC | 0.025 | 0.7 |
mRNA | CR-1-31B | CTRPv2 | pan-cancer | AAC | 0.011 | 0.7 |